TRIPLE G 10mg

TRIPLE G 10 mg is a high-purity synthetic peptide that is an analogue of human incretin hormones. This substance, known in the scientific literature as Retatrutide, is classified as a triple agonist of the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG). The product is delivered as a lyophilized product in a sterile vial, which ensures the chemical stability of the molecule during transport and storage. Due to its unique structure, it is a valuable reference material in research on cellular metabolism, GPCR receptor signaling pathways and thermogenesis. Check also Triple G 20 mg

INTENDED FOR RESEARCH PURPOSES! All the above-mentioned properties are observed in laboratory tests, not performed on humans, they are for information purposes only. All information contained in the descriptions has not been approved by GIS, GIF or EFSA. The substance is not a medicine, food product or dietary supplement and is therefore not suitable for human consumption.

The product qualifies as a chemical reagent/reference material authorized for marketing in the EU. It can only be used for scientific research. Other information about the agent is included in the safety data sheet for the chemical substance, which we make available for viewing. Products are available only to institutions or private individuals associated with research or laboratory activities.

From a chemical point of view Retatrutide is a single peptide showing activity towards three different membrane receptors. It is a molecule designed to imitate the action of natural ligands, but with a modified amino acid sequence to change the affinity and half-life in laboratory conditions. This substance is the subject of intensive research in major research centers around the world, serving as a model in experiments on the regulation of glucose and lipid homeostasis.

Retatrutide is characterized by a complex chemical structure that enables it to have multidirectional molecular effects.

• Chemical name: Retatrutide
• Research code: LY3437943
• CAS number: 2381089-83-2
• Total formula: C221H342N46O68
• Molar mass: ~4731.33 g/mol
• Form: White to off-white freeze-dried powder
• Solubility: Soluble in water (requires reconstitution with bacteriostatic water or other suitable laboratory solvent).

Each batch of TRIPLE G 10mg is subjected to rigorous quality analysis. The guaranteed purity of the substance is at least 99%, which is confirmed by HPLC (High Performance Liquid Chromatography) tests.

• Analysis method: HPLC, Mass Spectrometry (MS).
• Impurities: Below the detection level for standard analytical methods used in peptide chemistry.
• Endotoxins: Low level, suitable for in vitro and in vivo studies in animal models.

As a chemical substance sensitive to external factors, LY3437943 requires appropriate storage conditions:

• Freeze-dried form: Store at room temperature in a shaded place, away from moisture. For long-term storage, a temperature of -20°C is recommended.
• After reconstitution: The solution should be stored at 2°C to 8°C (refrigerated). Do not refreeze once dissolved.
• Safety: When working with the reagent, use standard personal protective equipment (laboratory gloves, safety glasses, apron). Avoid contact with skin and mucous membranes.

In studies on cell lines and isolated receptors, Retatrutide shows strong binding affinity to human GIP, GLP-1 and glucagon receptors.

1. GIP receptor: The substance acts as a strong agonist, showing activity comparable to or superior to that of the natural GIP ligand. In vitro studies show an effect on pathways related to insulin secretion and lipid metabolism in adipocytes.
2. GLP-1 receptor: Activation of this receptor in the laboratory is associated with modulation of cAMP pathways.
3. Glucagon receptor: A unique feature of Retatrutide is its activity towards the glucagon receptor, which in research models translates into increased lipolysis and cellular thermogenesis.

TRIPLE G 10mg (Retatrutide) is used in a wide spectrum of scientific research, including:

• research on the mechanisms of obesity and type 2 diabetes on mouse models (DIO mice),
• analysis of receptor synergy in the endocrine system,
• research on fatty liver disease (NAFLD/NASH) and its biomarkers,
• assessment of the impact of polyacylation on the pharmacokinetics of peptides. The product is not a medicine and cannot be used in human medical procedures.

Main areas of research interest for substances:

• Modulation of satiety and hunger signals (behavioral studies on animals).
• Effects on glucose homeostasis and insulin sensitivity.
• Study of lipolysis processes induced by the action of glucagon.
• Analysis of the safety profile of multireceptor peptides.

Retatrutide (LY3437943), a novel GIP/GLP-1/glucagon receptor agonist – PubMed